J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug

Taking stock of the drug industry, from the lab to the medicine chest

January 13, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mario Tama/Getty Images STAT+ | J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug The purchase will give J&J an approved mental health drug and Intra-Cellular's pipeline of neuropsychiatric medicines. By Andrew Joseph STAT+ | GSK to buy cancer-focused IDRx in $1 billion deal GSK, which has been building up its cancer business, will get an experimental drug for a rare cancer known as GIST. By Andrew Joseph STAT+ | Biogen CEO confirms he's shopping for biotechs: 'We will be doing deals' In a pre-JPM interview, Chris Viehbacher says companies in rare disease, immunology, and neurology are of interest. By Adam Feuerstein Joe Buglewicz/Bloomberg STAT+ | Cigna, Centene, Walgreens drop out of J.P. Morgan conference Roughly a dozen companies that appeared on the initial JPM agenda appear to have dropped out of the conference. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser